EGFR and non-small cell lung carcinoma: This was proven true in many cases: Gleevec for chronic myeloid leukemia (CML) [21] and gastrointestinal stromal tumors (GIST) [22], Gefitinib for non-small cell lung cancer carrying hyperactive and mutated EGFR [23], and Vemurafenib for melanoma [24].